Effect of Ezetimibe/Atorvastatin Combination on Oxidized Low Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease or Coronary Artery Disease Equivalent

Azar, Rabih R.; Badaoui, Georges; Sarkis, Antoine; Azar, Mireille; Aydanian, Hermine; Harb, Serge C.; Achkouty, Guy; Kassab, Roland

doi:10.1016/j.amjcard.2010.03.016

Cited by 18 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was probably because the control animals were relatively young and inflammatory changes of the LV myocardium were mild. It has been reported that ezetimibe can reduce the levels of TNF-α, high-sensitivity C-reactive protein, and 8-hydroxydeoxyguanosine (Kalogirou et al, 2007;Nakamura et al, 2009;Azar et al, 2010), suggesting that the anti-inflammatory effect of ezetimibe may be attributable to inhibition of oxidative stress and remnant lipoproteins (Fukuda et al, 2010;Kurobe et al, 2011;Tobaru et al, 2013). Futher investigation of other inflammatory genes should be needed.…”

Section: Discussionmentioning

confidence: 96%

“…It has been reported that ezetimibe reduces the levels of LDL-cholesterol, oxidized LDL-cholesterol, and small dense LDL (sd-LDL) (Kalogirou et al, 2007;Azar et al, 2010). The landmark IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy was superior to statin therapy alone for reducing cardiovascular events in high-risk patients after acute coronary syndrome (Blazing et al, 2014).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia

Kato

Nishioka

Nomura

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 98%

Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia

Kato

Nishioka

Nomura

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

“…29 Based on an assumed s.d. of 8 U/l for the OxLDL response, 30 the study was projected to have 80% power to detect a difference of ∼7.2 U/l in the change from baseline in OxLDL.…”

Section: Methodsmentioning

confidence: 99%

Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial

Bays

Evans²,

Maki³

et al. 2012

Eur J Clin Nutr

View full text Add to dashboard Cite

Background/objectives:Elevated oxidized low-density lipoprotein (OxLDL) may promote inflammation, and is associated with increased risk of atherosclerotic coronary heart disease and worsening complications of diabetes mellitus. The primary objective of this study was to evaluate the efficacy of chitin-glucan (CG), alone and in combination with a potentially anti-inflammatory olive oil (OO) extract, for reducing OxLDL in subjects with borderline to high LDL cholesterol (LDL-C) levels.Subjects/methods:This 6-week, randomized, double-blind, placebo-controlled study of a novel, insoluble fiber derived from the Aspergillus niger mycelium, CG, evaluated 130 subjects free of diabetes mellitus with fasting LDL-C 3.37–4.92 mmol/l and glucose ⩽6.94 mmol/l. Participants were randomly assigned to receive CG (4.5 g/day; n=33), CG (1.5 g/day; n=32), CG (1.5 g/day) plus OO extract (135 mg/day; n=30), or matching placebo (n=35).Results:Administration of 4.5 g/day CG for 6 weeks significantly reduced OxLDL compared with placebo (P=0.035). At the end of study, CG was associated with lower LDL-C levels relative to placebo, although this difference was statistically significant only for the CG 1.5 g/day group (P=0.019). CG did not significantly affect high-density lipoprotein cholesterol, triglycerides, glucose, insulin or F2-isoprostane levels. Adverse events did not substantively differ between treatments and placebo.Conclusions:In this 6-week study, CG (4.5 g/day) reduced OxLDL, an effect that might affect the risk for atherosclerosis.

show abstract

“…Recently, Azar et al [16] demonstrated that ezetimibe compared to placebo, on top of atorvastatin, strongly reduced oxLDL in patients with CAD. Evidently, the ezetimibe group had a larger reduction in LDL-C.…”

Section: Anti-inflammatory Effects Of E10/s20 and S80mentioning

confidence: 98%

Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin

Pesaro

Serrano

Fernandes

et al. 2012

International Journal of Cardiology

View full text Add to dashboard Cite

These data suggest that among stable CAD patients treated with S20, (1) both E10/S20 and S80 were equally effective in further reducing LDL-C; (2) neither treatment had any further significant anti-inflammatory effects; and (3) E10/S20 was more effective than S80 in inhibiting platelet aggregation. Thus, despite similar lipid lowering and doses 4× less of simvastatin, E10/S20 induced a greater platelet inhibitory effect than S80.

show abstract

Effect of Ezetimibe/Atorvastatin Combination on Oxidized Low Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease or Coronary Artery Disease Equivalent

Cited by 18 publications

References 30 publications

Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia

Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia

Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial

Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin

Contact Info

Product

Resources

About